Tricida, Inc., is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.
Learn More
CKD is a serious condition characterized by the gradual loss of essential kidney functions over time. In patients with CKD, normal fluid and electrolyte balance can no longer be maintained…
Learn More
Our investigational drug, TRC101 is a novel, non-absorbed polymer that is designed to bind…
Learn More
Tricida Announces Second Quarter 2018 Financial Results and Provides Update on Key Initiatives
Learn More
Tricida, Inc., is a late-stage pharmaceutical company focused on the development…
Learn More